DexCom, Inc. $DXCM Shares Acquired by Gradient Investments LLC

Gradient Investments LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 332,006 shares of the medical device company’s stock after buying an additional 40,343 shares during the period. Gradient Investments LLC’s holdings in DexCom were worth $22,035,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in DexCom during the 2nd quarter worth $453,279,000. Groupama Asset Managment increased its holdings in shares of DexCom by 79,043.1% during the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock valued at $350,601,000 after purchasing an additional 4,011,438 shares during the period. Marshall Wace LLP raised its stake in shares of DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after purchasing an additional 2,762,504 shares in the last quarter. Holocene Advisors LP acquired a new stake in DexCom in the third quarter worth about $163,964,000. Finally, CIBC Private Wealth Group LLC lifted its holdings in DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after purchasing an additional 2,294,709 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00. Following the sale, the executive vice president directly owned 112,904 shares of the company’s stock, valued at $7,321,824.40. The trade was a 1.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have commented on DXCM. Wells Fargo & Company lowered their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Robert W. Baird set a $87.00 price target on shares of DexCom in a research note on Friday, February 13th. Evercore began coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Finally, Piper Sandler reissued an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $85.50.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $66.95 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $25.77 billion, a price-to-earnings ratio of 31.88, a PEG ratio of 1.30 and a beta of 1.48. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a 50-day moving average of $70.50 and a two-hundred day moving average of $68.03.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the firm earned $0.45 EPS. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.